Therapeutic protein administration in both preclinical and clinical studies can result in the formation of anti‐drug antibodies against the therapeutic protein. Anti‐drug antibody formation may alter the pharmacokinetics of the therapeutic protein, reduce its plasma concentrations, increase exposure variability, and may lead to a loss of efficacy and adverse events. In an effort to quantitatively understand the effect of anti‐drug antibodies on the concentration‐time profile of a therapeutic protein, as well as develop effective strategies to mitigate its impact in the preclinical and clinical development of therapeutic proteins, mathematical models have been developed to characterize the therapeutic protein pharmacokinetics and its modulation by anti‐drug antibodies in vivo. Here, we review several different mechanism‐based modeling frameworks, summarize their approaches to predict immunogenicity effects, and explore the merits and limitations of each model.
Background/Objectives: The administration of human monoclonal antibodies (mAb) in preclinical pharmacokinetics and toxicology studies often triggers an immune response, leading to the formation of anti-drug antibodies (ADA). To mitigate this effect, we have recently performed and reported on studies using short-term immunosuppressive regimens to induce prolonged immune tolerance towards a human mAb, erenumab, in rats. Here, we report on the development of a semi-mechanistic modeling approach that quantitatively integrates pharmacokinetic and immunogenicity assessments from immune tolerance induction studies to provide a framework for the simulation-based evaluation of different immune induction scenarios for the maintenance of prolonged immune tolerance towards human mAbs. Methods: The integrated pharmacokinetic/pharmacodynamic (PK/PD) modeling approach combined a semi-mechanistic model of the adaptive immune system to predict ADA formation kinetics with a population pharmacokinetic model to assess the impact of the time course of the ADA magnitude on the PK of erenumab in rats. Model-derived erenumab concentration–time profiles served as input for a quantitative system pharmacology-style semi-mechanistic model of the adaptive immune system to conceptualize the ADA response as a function of the kinetics of CD4+ T helper cells and T regulatory cells. Results: The model adequately described the observed ADA magnitude–time profiles in all treatment groups and reasonably simulated the kinetics of selected immune cells responsible for ADA formation. It also successfully captured the impact of tacrolimus/sirolimus immunomodulation on ADA formation, demonstrating that the regimen effectively suppressed ADA formations and induced immune tolerance. Conclusions: This work demonstrates the utility of modeling approaches to integrate pharmacokinetic and immunogenicity assessment data for the prospective planning of long-term toxicology studies to support the preclinical development of mAbs.
25 June 2026 in Journal of Pharmacokinetics and Pharmacodynamics
Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal antibodies (mAbs) compared to other drugs, given that the intrinsic properties of immunoglobulin G molecules are generally considered ethnically insensitive. This prompted an evaluation of the currently available evidence for potential PK differences for mAbs between Japanese and Non‐Japanese populations. We reviewed 137 mAbs approved in the United States, of which 101 were also approved in Japan, to evaluate whether PK differences between Japanese and non‐Japanese individuals have been reported. PK was found to be similar between Japanese and non‐Japanese, predominantly Caucasians/Whites, for 59 out of 101 mAbs. Although PK differences were identified for 26 out of 101 mAbs approved in Japan, these differences were largely attributed to body weight differences between Japanese and non‐Japanese populations. After adjusting for these body weight differences, most mAbs demonstrated no meaningful PK differences across the ethnic groups. Importantly, the observed differences were reported not to translate into clinically meaningful impact on pharmacodynamics, safety, and efficacy to warrant different dosing recommendations. No differences in dosing recommendations could be detected for any of the 101 mAbs approved in Japan compared to the United States. Overall, these data suggest a lack of a convincing scientific rationale for the necessity of dedicated PK studies in Japanese versus non‐Japanese individuals for mAbs.